MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
May 15, 2019 17:07 ET
|
MacroGenics, Inc.
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy)Oral abstract will be presented at American...
Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual Meeting
May 15, 2019 17:01 ET
|
Oncternal Therapeutics
SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., a clinical-stage biotechnology company focused on developing potential first-in-class therapeutic candidates for cancers...
Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy
May 15, 2019 17:01 ET
|
Cybrexa Therapeutics
Results support the potential of alphalex™ technology with diverse range of anticancer agents Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP...
Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
May 15, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting
May 15, 2019 08:10 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s...
Avant Diagnostics, Inc. Corporate Update
May 08, 2019 15:28 ET
|
Avant Diagnostics, Inc.
Washington, DC, May 08, 2019 (GLOBE NEWSWIRE) -- Avant Diagnostics, Inc. hereby provides the following corporate update to the Company’s shareholders. A copy of the update can also be found on the...
Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update
May 07, 2019 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in...
VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 01, 2019 08:00 ET
|
VBI Vaccines, Inc.
All four lead pipeline programs progressing towards expected clinical milestones in 2019Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine,...
VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call
April 23, 2019 08:00 ET
|
VBI Vaccines, Inc.
10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at...
Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
April 17, 2019 16:05 ET
|
Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors; Advanced cutaneous melanomaIntratumoral administration of PV-10 to visceral and superficial disease locationsSingle-agent and combination therapy treatment settings ...